
May 23 (Reuters) - Gilead Sciences Inc GILD.O:
ASCENT-03: TRODELVY® DEMONSTRATES HIGHLY STATISTICALLY SIGNIFICANT & CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION FREE SURVIVAL IN PATIENTS WITH FIRST-LINE METASTATIC TRIPLE-NEGATIVE BREAST CANCER WHO ARE NOT CANDIDATES FOR CHECKPOINT INHIBITORS
GILEAD SCIENCES INC - ASCENT-03 STUDY MEETS PRIMARY ENDPOINT WITH SIGNIFICANT IMPROVEMENT IN PFS
GILEAD SCIENCES INC - TRODELVY SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES IN ASCENT-03
GILEAD SCIENCES INC - NO OS DETRIMENT OBSERVED IN ASCENT-03 STUDY